"U.S. officials on Tuesday ordered 600,000 doses of Covid-19 treatment sotrovimab, the only monoclonal antibody therapy thought to work against the Omicron variant, as a record number of cases puts hospitals under pressure in parts of the U.S. and Europe.
Sotrovimab, made by GlaxoSmithKline PLC and Vir Biotechnology Inc., is now the only Covid-19 monoclonal antibody available for patients in the U.S. The government paused distribution of two other treatments, made by Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. in late December, after early tests suggested they lost effectiveness against the new strain.
The new doses, which Glaxo and Vir have promised to deliver throughout the first quarter, should significantly boost supplies of sotrovimab in the U.S.
The pricing for this order wasn't disclosed by the companies or government. A spokeswoman for Glaxo said the details of the deal are proprietary and that the pricing structure was agreed upon through multiple contracts and contract modifications. The government in November agreed to buy 300,000 doses of the treatment, building on an earlier, smaller order.
Monoclonal antibodies mimic a part of the body's immune response to the virus and are typically used at an early stage of infection to lessen the risk of serious illness.
In a large clinical trial, conducted during an earlier wave of the pandemic, sotrovimab reduced the risk of hospitalization or death by 79% in people with mild or moderate Covid-19 at high risk of progressing to severe disease." [1]
1. U.S. News: U.S. Strikes Deal for Antibody Therapy
Roland, Denise. Wall Street Journal, Eastern edition; New York, N.Y. [New York, N.Y]. 12 Jan 2022: A.8.
Komentarų nėra:
Rašyti komentarą